Carfilzomib combination approved for use in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of carfilzomib (Kyprolis┬«) in combination with dexamethasone for myeloma patients who have received at least one previous treatment. The approval is based on results from the ENDEAVOR trial which showed that progression-free survival was significantly improved in patients treated with carfilzomib in combination with dexamethasone compared…

Details